Compare Vertex Pharmaceuticals Incorporated (VRTX) vs Wipro Limited (WIT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vertex Pharmaceuticals Incorporated vs Wipro Limited — how do they compare? Vertex Pharmaceuticals Incorporated trades at $522.29 (market cap $134.06B), while Wipro Limited trades at $1.69 (market cap $17.95B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 7.5× Wipro Limited's market cap, and Wipro Limited pays a 5.01% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals.
| VRTX | WIT | |
|---|---|---|
Market Cap | $134.06B | $17.95B |
Sector | Health | Technology |
52-Week High | $557.96 | $3.06 |
52-Week Low | $376.62 | $1.68 |
Enterprise Value | $128.18B | $16.02B |
Dividend Yield | — | 5.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Vertex Pharmaceuticals (VRTX) trades at $528.9, down 3.15% on the day, amid a mixed technical and fundamental backdrop. The stock shows a bullish moving average signal but neutral oscillators, with key support at $522. Fundamentally, 2025 revenue reached $12.0B with a strong net income margin of 35%, though recent quarterly EPS results have been mixed. The company recently completed the acquisition of Crinetics Pharmaceuticals, signaling growth ambitions.
The outlook remains positive given analyst consensus favoring a Buy rating (84%) and a $548.78 price target, implying upside. Key opportunities include revenue growth from new drug launches, while risks involve competitive pressures and earnings volatility. The stock's current valuation at a P/E of 30.8 requires sustained execution to justify further gains.
WIT trades at $1.73, down 4.42% today, with bearish technical signals and mixed earnings performance. Recent quarters show earnings misses against expectations, though the company maintains strong profitability with 13.92% net margin and 16.09% ROE. Positive business developments include renewed partnerships with ABB and Databricks to enhance digital and AI services.
The outlook is cautious due to earnings volatility and bearish analyst sentiment, with only 19% buy ratings. Risks include competitive pressures and macroeconomic uncertainty affecting tech spending. The stock's valuation appears reasonable with P/E of 12.98, but investor confidence hinges on improved earnings consistency and margin stability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →About Wipro Limited
Wipro is a leading global IT services provider, with 175,000 employees. Based in Bengaluru, this India IT services firm leverages its offshore outsourcing model to derive over half of its revenue (57%) from North America. The company offers traditional IT services offerings: consulting, managed services, and cloud infrastructure services as well as business process outsourcing as a service.
Read more on WIT →
